Isolated Lung Perfusion for Pulmonary Metastases

Thoracic Surgery Clinics

Volumn 16, Issue 2, 2006, Pages 185-198

  Hendriks, Jeroen M H ^a   Van Putte, Bart P ^b   Grootenboers, Marco ^b   Van Boven, Wim J ^b   Schramel, Franz ^b   Van Schil, Paul E Y ^a  

^a ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^b ST ANTONIUS HOSPITAL   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; DOXORUBICIN; FLOXURIDINE; GEMCITABINE; MELPHALAN; PACLITAXEL; TUMOR NECROSIS FACTOR ALPHA;

ANTINEOPLASTIC ACTIVITY; BLOOD TOXICITY; CANCER; CANCER SURVIVAL; DOG; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; EXPERIMENTAL MODEL; HUMAN; HYPOTENSION; ISOLATED LUNG PERFUSION; LUNG METASTASIS; LUNG PERFUSION; LUNG TOXICITY; NEUROLOGIC DISEASE; NONHUMAN; PRIORITY JOURNAL; REVIEW; SURGICAL TECHNIQUE; SWINE; THORACOTOMY; THROMBOCYTOPENIA;

ANIMALS; ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, CANCER, REGIONAL PERFUSION; HUMANS; LUNG NEOPLASMS; MODELS, ANIMAL; RATS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33646559205     PISSN: 15474127     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thorsurg.2005.11.003     Document Type: Review

References (82)

1. Ranney D. Drug targeting to the lungs. Biochem Pharmacol 35 (1986) 1063-1069
2. Pastorino U., Buyse M., Friedel G., et al. Long-term results of lung metastasectomy: prognostic analyses based on 5206 cases. The International Registry of Lung Metastases. J Thorac Cardiovasc Surg 113 (1997) 37-49
3. Creech O., Krementz E.T., Ryan R.F., et al. Chemotherapy of cancer: regional perfusion utilizing an extracorporeal circuit. Ann Surg 148 (1958) 616-632
4. Eggermont A., de Wilt J., and ten Hagen T. Current uses of isolated limb perfusion in the clinic and a model system for new strategies. Review Article. Lancet Oncol 4 (2003) 429-437
5. Johnston M.R., Minchin R., Shull J.H., et al. Isolated lung perfusion with adriamycin. A preclinical study. Cancer 52 (1983) 404-409
6. Johnston M.R., Christensen C.W., Minchin R.F., et al. Isolated total lung perfusion as a means to deliver organ-specific chemotherapy: long-term studies in animals. Surgery 98 (1985) 35-44
7. Johnston M.R., Minchen R.F., and Dawson C.A. Lung perfusion with chemotherapy in patients with unresectable metastatic sarcoma to the lung or diffuse bronchioloalveolar carcinoma. J Thorac Cardiovasc Surg 110 (1995) 368-373
8. Minchin R.F., Johnston M.R., Schuller H.M., et al. Pulmonary toxicity of doxorubicin administered by in situ isolated lung perfusion in dogs. Cancer 61 (1988) 1320-1325
9. Baciewicz F.A., Arredondo M., Chaudhuri B., et al. Pharmacokinetics and toxicity of isolated lung perfusion of lung with doxorubicin. J Surg Res 50 (1991) 124-128
10. Bongard R., Roerig D., Johnston M., et al. Influence of temperature and plasma protein on doxorubicin uptake by isolated lungs. Drug Metab Dispos 21 (1993) 428-434
11. Rickaby D., Fehring J., Johnston M., et al. Tolerance of the isolated perfused lung to hyperthermia. J Thorac Cardiovasc Surg 101 (1991) 732-739
12. Cowen M., Mulvin D., Howard R., et al. Lung tolerance to hyperthermia by in vivo perfusion. Eur J Cardiothorac Surg 6 (1992) 167-173
13. Pass H.I., Mew D.J., Kranda K.C., et al. Isolated lung perfusion with tumor necrosis factor for pulmonary metastases. Ann Thorac Surg 61 (1996) 1609-1617
14. Ratto G.B., Toma S., Civalleri D., et al. Isolated lung perfusion with platinum in the treatment of pulmonary metastases from soft tissue sarcomas. J Thorac Cardiovasc Surg 112 (1996) 614-622
15. Burt M.E., Liu D., Abolhoda A., et al. Isolated lung perfusion for patients with unresectable metastases from sarcoma: a phase I trial. Ann Thorac Surg 69 (2000) 1542-1549
16. Hendriks J.M., Grootenboers M.J., Schramel F.M., et al. Isolated lung perfusion with melphalan for resectable lung metastases: a phase I clinical trial. Ann Thorac Surg 78 (2004) 1919-1927
17. Miller B., and Rosenbaum A. The vascular supply to metastatic tumors of the lung. Surg Gynecol Obstet 125 (1967) 1009-1016
18. Milne E., Noonan C., Margulis A., et al. Vascular supply of pulmonary metastases. Experimental study in rats. Invest Radiol 4 (1969) 215-229
19. Haller J., Bron K., Wholey M., et al. Selective bronchial artery catheterization for diagnostic and physiologic studies and chemotherapy for bronchogenic carcinoma. J Thorac Cardiovasc Surg 51 (1966) 143-152
20. Jinbo M., Ueda K., Kaneda Y., et al. Video-assisted transcatheter lung perfusion regional chemotherapy. Eur J Cardiothorac Surg 27 (2005) 1079-1082
21. Furrer M., Lardinois D., Thormann W., et al. Isolated lung perfusion: single-pass system versus recirculating blood perfusion in pigs. Ann Thorac Surg 65 (1998) 1420-1425
22. Pogrebniak H., Witt C., Terrill R., et al. Isolated lung perfusion with tumor necrosis factor: a swine model in preparation of human trials. Ann Thorac Surg 57 (1994) 1477-1483
23. Schrump D.S., Zhai S., Nguyen D.M., et al. Pharmacokinetics of paclitaxel administered by hyperthermic retrograde isolated lung perfusion techniques. J Thorac Cardiovasc Surg 123 (2002) 686-694
24. Weksler B., Schneider A., Ng B., et al. Isolated single lung perfusion in the rat. J Appl Physiol 74 (1993) 2736-2739
25. Wang H.Y., Port J.L., Hochwald S., et al. Revised technique of isolated lung perfusion in the rat. Ann Thorac Surg 60 (1995) 211-212
26. Hendriks J., Van Schil P., and Eyskens E. Modified technique of isolated left lung perfusion in the rat. Eur Surg Res 31 (1999) 93-96
27. Van Putte B.P., Hendriks J.M.H., Romijn S., et al. Single-pass isolated lung perfusion versus recirculating isolated lung perfusion with melphalan in a rat model. Ann Thorac Surg 74 (2002) 893-898
28. Krueger T., Kümmerie A., Vallet C., et al. Antegrade and retrograde isolated lung perfusion with doxorubicin in the rat: comparison of pharmacokinetics and toxicity. Eur Respir J 20 (2002) s179
29. Romijn S., Hendriks J., Van Putte B., et al. Anterograde versus retrograde isolated lung perfusion with melphalan in the WAG-Rij rat. Eur J Cardiothorac Surg 27 (2005) 1083-1085
30. Nawata S., Abolhoda A., Ross H., et al. Sequential bilateral isolated lung perfusion in the rat: an experimental model. Ann Thorac Surg 63 (1997) 796-799
31. Blades B., Pierpoint H., Samadi A., et al. Effect of experimental lung ischemia on pulmonary function: a preliminary report. Surg Forum 4 (1953) 255
32. Weksler B., Lenert J., Ng B., et al. Isolated single lung perfusion with doxorubicin is effective in eradicating soft tissue sarcoma lung metastases in a rat model. J Thorac Cardiovasc Surg 107 (1994) 50-54
33. Ng B., Lenert J.T., Weksler B., et al. Isolated lung perfusion with FUDR is an effective treatment for colorectal adenocarcinoma lung metastases in rats. Ann Thorac Surg 59 (1995) 205-208
34. Hendriks J.M., Van Schil P.E., De Boeck G., et al. Isolated lung perfusion with melphalan and tumor necrosis factor for metastatic pulmonary adenocarcinoma. Ann Thorac Surg 66 (1998) 1719-1725
35. Wexler H. Accurate identification of experimental pulmonary metastases. J Natl Cancer Instit 36 (1966) 641-645
36. Abolhoda A., Brooks A., Nawata S., et al. Isolated lung perfusion with doxorubicin prolongs survival in a rodent model of pulmonary metastases. Ann Thorac Surg 64 (1997) 181-184
37. Linder A., Friedel G., Fritz P., et al. The ex-vivo isolated, perfused human lung model: description and potential applications. Thorac Cardiovasc Surg 44 (1996) 140-146
38. Asher A., Mulé J.J., Reichert C., et al. Studies on the anti-tumor efficacy of systemically administered recombinant tumor necrosis factor against several murine tumors in vivo. J Immunol 138 (1987) 963-974
39. Weksler B., Blumberg D., Lenert J., et al. Isolated single-lung perfusion with TNF-α in a rat sarcoma lung metastases model. Ann Thorac Surg 58 (1994) 328-332
40. Brooks A., Ng B., Liu D., et al. Specific organ gene transfer in vivo by regional organ perfusion with herpes viral amplicon vectors: implications for local gene therapy. Surgery 129 (2001) 324-334
41. Manusama E., Durante N., Marquet R., et al. Ischemia promotes anti-tumor effect of tumour necrosis factor alpha in isolated limb perfusion in the rat. Reg Cancer Treat 7 (1994) 155-159
42. Fraker D.L., Alexander H.R., and Pass H.I. Biologic therapy of tumor necrosis factor: clinical applications by systemic and regional administration. In: DeVita V., Hellman S., and Rosenberg S.A. (Eds). Biologic therapy of cancer. 2nd ed (1995), Lippincott, Philadelphia 329-346
43. Ellis J., Ng B., Port J., et al. Isolated lung perfusion with carboplatin for metastatic sarcoma in the F344 rat. Surg Forum XLV (1994) 294-295
44. Li T.S., Sugi K., Ueda K., et al. Isolated lung perfusion with cisplatin in a rat lung solitary tumor nodule model. Anticancer Res 18 (1998) 4171-4176
45. Van Putte B.P., Hendriks J.M., Romijn S., et al. Combination chemotherapy with gemcitabine with isolated lung perfusion for the treatment of pulmonary metastases. J Thorac Cardiovasc Surg 130 (2005) 125-130
46. Li T.S., Kaneda Y., Saeki K., et al. Pharmacokinetic differences between rat tumour and lung tissues following isolated lung perfusion with cisplatin. Eur J Cancer 35 (1999) 1846-1850
47. Saeki K., Kaneda Y., Li T.S., et al. Pharmacokinetic characteristic in tumor tissue following isolated lung perfusion with CDDP - an experimental study in solitary pulmonary sarcoma model in rat. J Surg Oncol 75 (2000) 193-196
48. Tanaka T., Kaneda Y., Li T.S., et al. Digitonin enhances the antitumor effect of cisplatin during isolated lung perfusion. Ann Thorac Surg 72 (2001) 1173-1178
49. Miller R. Interaction between digitonin and bilayer membranes. Biochim Biophys Acta 774 (1984) 151-157
50. Vercesi A., Bernardes C., Hoffmann M., et al. Digitonin permeabilization doest not affect mitochondrial function and allows the determination of the mitochondrial membrane potential of Trypansosoma cruzi in situ. J Biol Chem 266 (1991) 14431-14434
51. Ratto G., Esposito M., Leprini A., et al. In situ lung perfusion with cisplatin. Cancer 71 (1993) 2962-2970
52. Franke U., Wittwer H., Kaluza M., et al. Evaluation of isolated lung perfusion as neoadjuvant therapy of lung metastases using a novel in vivo pig model: II. High-dose cisplatin is well tolerated by the native lung tissue. Eur J Cardiothorac Surg 26 (2004) 800-806
53. Schröder C., Fisher S., Pieck A.C., et al. Technique and results of hyperthermic isolated lung perfusion with high-doses of cisplatin for the treatment of surgically relapsing or unresectable lung sarcoma metastasis. Eur J Cardiothorac Surg 22 (2002) 41-46
54. Gewirtz D.A. A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. Biochem Pharmacol 57 (1999) 727-741
55. Minchin R.F., and Boyd M.R. Uptake and metabolism of doxorubicin in isolated perfused rat lung. Biochem Pharmacol 32 (1983) 2829-2832
56. Minchin R.F., Johnston M.R., Aiken M.A., et al. Pharmacokinetics of doxorubicin in isolated lung of dogs and humans perfused in vivo. J Pharmacol Exp Ther 229 (1984) 193-198
57. Benjamin R., Riggs C., and Bachur N. Plasma pharmacokinetics of adriamycin and its metabolites in humans with normal hepatic and renal function. Cancer Res 37 (1977) 1416-1420
58. Ng B., Hochwald S., and Burt M. Isolated lung perfusion with doxorubicin reduces cardiac and host toxicities associated with systemic administration. Ann Thorac Surg 61 (1996) 969-972
59. Weksler B., Ng B., Lenert J., et al. Isolated single-lung perfusion with doxorubicin is pharmacokinetically superior to intravenous injection. Ann Thorac Surg 56 (1993) 209-214
60. Port J., Hochwald S., Wang H., et al. Buthionine sufoximine pre-treatment potentiates the effect of isolated lung perfusion with doxorubicin. Ann Thorac Surg 60 (1995) 239-243
61. Putnam Jr. J.B. New and evolving treatment methods for pulmonary metastases. Semin Thorac Cardiovasc Surg 14 (2002) 49-56
62. Nawata S., Abecasis N., Ross H., et al. Isolated lung perfusion with melphalan for the treatment of metastatic pulmonary sarcoma. J Thorac Cardiovasc Surg 112 (1996) 1542-1548
63. Ueda K., Sugi K., Li T.S., et al. The long-term evaluation of pulmonary toxicity following isolated lung perfusion with melphalan in the rat. Anticancer Res 19 (1999) 141-148
64. Hendriks J.M., Van Schil P.E., Van Oosterom A.A., et al. Isolated lung perfusion with melphalan prolongs survival in a rat model of metastatic pulmonary adenocarcinoma. Eur Surg Res 31 (1999) 267-271
65. Romijn S., Hendriks J., Van Putte B., et al. Variations in flow, duration and concentration do not change the final lung concentration of melphalan after isolated lung perfusion in rats. Eur Surg Res 35 (2003) 50-53
66. Romijn S., Hendriks J., Van Putte B., et al. Regional differences of melphalan lung levels after isolated lung perfusion in the rat. J Surg Res 125 (2005) 157-160
67. Briele H., Djuric M., Jung D., et al. Pharmacokinetics of melphalan in clinical isolated perfusion of the extremities. Cancer Res 45 (1985) 1885-1889
68. Abolhoda A., Brooks A., Choudhry M., et al. Characterization of local inflammatory response in an isolated lung perfusion model. Ann Surg Oncol 5 (1998) 87-92
69. Sandler A., and Ettinger D.S. Gemcitabine: single-agent and combination therapy in non-small cell lung cancer. Oncologist 4 (1999) 241-251
70. Storniolo A.M., Enas N.H., Brown C.A., et al. An investigational new drug treatment program for patients with gemcitabine: results for over 3000 patients with pancreatic carcinoma. Cancer (Phila.) 85 (1999) 1261-1268
71. Van Putte B.P., Hendriks J.M., Romijn S., et al. Isolated lung perfusion with gemcitabine in a rat: pharmacokinetics and survival. J Surg Res 109 (2003) 118-122
72. Van Putte B.P., Hendriks J.M., Romijn S., et al. Pharmacokinetics after pulmonary artery perfusion with gemcitabine. Ann Thorac Surg 76 (2003) 1036-1040
73. van Moorsel C., Peters G., and Pinedo H. Gemcitabine: future prospects of single-agent and combination studies. Oncologist 2 (1997) 127-134
74. Patel S., Papadopoulos N., Plager C., et al. Phase II study of paclitaxel in patients with previously treated osteosarcoma and its variants. Cancer 78 (1996) 741-744
75. Maier-Lenz H., Hauns B., Haering B., et al. Phase I study of paclitaxel administered as a 1-hour infusion: toxicity and pharmacokinetics. Semin Oncol 24 (1997) S1916-S1919
76. Kelly H., and Goldberg R. Systemic therapy for metastatic colorectal cancer: current options, current evidence. J Clin Oncol 23 (2005) 4553-4560
77. Port J., Ng B., Ellis J., et al. Isolated lung perfusion with FUDR in the rat : pharmacokinetics and survival. Ann Thorac Surg 62 (1996) 848-852
78. Smyth N., and Blades B. Selective chemotherapy of the lung during unilateral pulmonary artery occlusion with a balloon-tipped catheter. J Thorac Cardiovasc Surg 40 (1960) 653-666
79. Karakousis C.P., Park H.C., Sharma S.D., et al. Regional chemotherapy via the pulmonary artery for pulmonary metastases. J Surg Oncol 18 (1981) 249-255
80. Wang H.Y., Ng B., Ahrens C., et al. Unilateral pulmonary artery occlusion inhibits growth of metastatic sarcoma in the rat lung. J Surg Oncol 57 (1994) 183-186
81. Furrer M., Lardinois D., Thormann W., et al. Cytostatic lung perfusion by use of an endovascular blood flow occlusion technique. Ann Thorac Surg 65 (1998) 1523-1528
82. Lee R., Boasquevisque C., Boglione M., et al. Isolated lung liposome-mediated gene transfer produces organ-specific transgenic expresssion. Ann Thorac Surg 66 (1998) 903-907